Biologics Market Transparency Act of 2022

12/29/2022, 4:48 PM

Biologics Market Transparency Act of 2022

This bill requires biologics manufacturers to notify the Food and Drug Administration in advance of withdrawing a product from sale.

Congress
117
Number
S - 4302
Introduced on
2022-05-25
# Amendments
0
Sponsors
+5
Cosponsors
+5

Variations and Revisions

5/25/2022
Text
PDF
XML

Status of Legislation

Bill Introduced
Introduced to House
House to Vote
Introduced to Senate
Senate to Vote

Purpose and Summary

Biologics Market Transparency Act of 2022

This bill requires biologics manufacturers to notify the Food and Drug Administration in advance of withdrawing a product from sale.

Alternative Names
Official Title as IntroducedA bill to amend the Federal Food, Drug, and Cosmetic Act to require prompt reports of marketing status by holders of approved applications for biological products, and for other purposes.
Policy Areas
Health

Comments

Related

Bill Update Alert:  FDASLA Act of 2022

Recent Activity

Latest Summary10/21/2022

Biologics Market Transparency Act of 2022

This bill requires biologics manufacturers to notify the Food and Drug Administration in advance of withdrawing a product from sale.

Latest Action5/25/2022
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S2709)